Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/15/2003WO2003039437A2 Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
05/15/2003WO2003039434A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
05/15/2003WO2003039418A1 Compositions for the treatment of infectious diseases
05/15/2003WO2003039382A2 System for processing tissue
05/15/2003WO2003039346A2 Diagnostics and therapeutics for ocular abnormalities
05/15/2003WO2003039342A2 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
05/15/2003WO2003039331A2 Method for improving stability of a bone-connecting implant
05/15/2003WO2003039232A2 Endothelial cell derived hemotopoietic growth factor
05/15/2003WO2003039225A2 Antigen arrays comprising rankl for treatment of bone disease
05/15/2003WO2003026397A3 Thyrotropin releasing hormone receptor disruptions, compositions and methods relating thereto
05/15/2003WO2003025171A3 Modulation of retinoic acid receptor gene expression and therapeutic uses thereof
05/15/2003WO2002100836A3 Compounds, compositions and methods for modulating beta-amyloid production
05/15/2003WO2002097032A3 Proteins associated with cell growth, differentiation, and death
05/15/2003WO2002094856A3 Gpe analogs and peptidomimetics
05/15/2003WO2002092115A3 Method of preventing cell death using segments of neural thread proteins
05/15/2003WO2002085289A3 Modulators of angiogenesis
05/15/2003WO2002083926A3 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
05/15/2003WO2002083179A3 Fusion proteins
05/15/2003WO2002068657A3 Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
05/15/2003WO2002068637A8 Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
05/15/2003WO2002064795A3 Putative human enzymes
05/15/2003WO2002064046A3 A compound and method of treatment for fungal pathologies of the oral cavity
05/15/2003WO2002063003A3 Platlet glycoprotein ib alpha fusion polypeptides and methods of use thereof
05/15/2003WO2002058730A3 Compositions for treatment of ocular neovascularization
05/15/2003WO2002058720A3 Angiogenically effective unit dose of fgf-2 and method of use
05/15/2003WO2002057298A3 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
05/15/2003WO2002056027A3 Regulation of neutral development by daedalos
05/15/2003WO2002055108A9 Targeted modification of intracellular compounds
05/15/2003WO2002054940A3 Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
05/15/2003WO2002048366A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002040654A3 A human serpin secreted from lymphoid cells lsi-01
05/15/2003WO2002040016A8 Association of calpain inhibitors and reactive oxygen species trapping agents
05/15/2003WO2002038606A3 Compositions and methods relating to ovary specific genes and proteins
05/15/2003WO2002034285A3 Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
05/15/2003WO2002030462A9 Hedgehog antagonists, methods and uses related thereto
05/15/2003WO2002029059A9 Nogo receptor homologs
05/15/2003WO2002029031A3 Isoprenoid-dependent ras anchorage (idra) proteins
05/15/2003WO2002029025A9 Factor vii glycoforms
05/15/2003WO2002026987A3 A human g-protein coupled receptor, hgprbmy6, expressed highly in small intestine
05/15/2003WO2002026981A3 Human protease inhibitor proteins and polynucleotides encoding the same
05/15/2003WO2002026781A9 Ige receptor antagonists
05/15/2003WO2002018424A3 Nucleic acids and polypeptides
05/15/2003WO2002018407A9 Antisense oligonucleotides against vanilloid receptor 1
05/15/2003WO2002014348A3 Glycoproteins and methods of use thereof
05/15/2003WO2002004423A9 Thrombin inhibitors comprising an aminoisoquinoline group
05/15/2003WO2001080832A3 Administration of a thiol-based chemoprotectant compound
05/15/2003WO2001071309A3 Methods and reagents for regulation of cellular responses in biological systems
05/15/2003US20030093821 For therapy of human subject diagnosed for predisposition for increased serum cholesterol or LDL cholesterol
05/15/2003US20030093819 Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
05/15/2003US20030092902 Fusion protein for use in the treatment body weight disorders
05/15/2003US20030092900 Meth1 and Meth2 polynucleotides and polypeptides
05/15/2003US20030092899 Polynucleotide functionally coding for the LHP protein from Mycobacterium tuberculosis, its biologically active derivative fragments, as well as methods using the same
05/15/2003US20030092898 Nucleotide sequences coding polypeptide for use in diagnosis, monitoring, classification, imaging and treatment of mamary gland cancer
05/15/2003US20030092895 Human potassium channel 1 and 2 proteins
05/15/2003US20030092894 Conjugated antigen for use as tool in the treatment of cancer
05/15/2003US20030092893 Antibody for use in the diagnosis of cancer, reproductive, kidney and nervous system disorders
05/15/2003US20030092892 Crosslinking, agglutination, purification
05/15/2003US20030092891 Expressed ligand - vascular intercellular signalling molecule
05/15/2003US20030092890 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/15/2003US20030092883 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer and nervous system disorders
05/15/2003US20030092881 Polypeptide for use in diagnosis and treatment of gastrointestinal disorders
05/15/2003US20030092800 Sustained release; drug delivery
05/15/2003US20030092764 Oxidation resistance
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092732 Eating disorders; dietetics; antiinflammatory agents; autoimmune diseases
05/15/2003US20030092684 Antiinflammatory agents, rheumatic diseases, autoimmune disease; administering tetracyclins
05/15/2003US20030092664 Regulation of human epithin-like serine protease
05/15/2003US20030092661 88kDa tumorigenic growth factor and antagonists
05/15/2003US20030092660 Antiproliferative agents; anticancer agents; urogenital systems; insertion into cells
05/15/2003US20030092659 Therapy for nervous system degradation
05/15/2003US20030092658 Novel human enzyme family members and uses thereof
05/15/2003US20030092657 PAX2 is a transcription factor; apoptosis activators or anticarcinogenic agents
05/15/2003US20030092656 Therapeutic agents for treatment of solid tumors comprising an expression-inhibiting sustance against Wilms' tumor gene (WT1)
05/15/2003US20030092655 Delivery system for nucleic acids
05/15/2003US20030092654 8-30 nucleotides targeted to a nucleic acid molecule encoding human Inhibitor-kappa B kinase alpha; gene expression inhibition; antiproliferative, anticancer and antiinflammatory agents
05/15/2003US20030092651 Tissue-specific and target RNA-specific ribozymes
05/15/2003US20030092650 Gene expression inhibition; treating developmental disorders or aberrant apoptosis
05/15/2003US20030092649 Antisense modulation of vascular endothelial growth factor receptor-2 expression
05/15/2003US20030092648 Antisense oligonucleotides for gene expression inhibition; antiproliferative agents
05/15/2003US20030092647 Antisense modulation of cholesteryl ester transfer protein expression
05/15/2003US20030092646 Method and reagent for the inhibition of CD20
05/15/2003US20030092645 Cloning, expression, viral and delivery vectors and hosts
05/15/2003US20030092638 Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
05/15/2003US20030092633 Preventing desensitization of receptors
05/15/2003US20030092632 Sulfated CCR5 peptides for HIV-1 infection
05/15/2003US20030092631 IGF antagonist peptides
05/15/2003US20030092630 Amino acid side chain-modified substrates of the enzyme; obtaining locally limited inhibition; treating inflammation, psoriasis, periodontitis, allergies, arthritis, tumors or autoimmune diseases
05/15/2003US20030092629 Inhibitors of memapsin 2 and use thereof
05/15/2003US20030092628 Gonadotropin releasing hormone antagonist
05/15/2003US20030092627 For treatment or prophylaxis of bleeding episodes; kits
05/15/2003US20030092626 Use in drug screening, diagnosis, prophylaxis and treatment of central dysfunction, inflammatory diseases, cardiovascular disorders, diabetes, immune system disorders or gastrointestinal disorders
05/15/2003US20030092625 Aqueous prolonged release formulation
05/15/2003US20030092624 Denaturant (boiling and/or detergent) stable; various uses including de-aggregating and/or preventing aggregation of an aggregating protein such as beta-amyloid or prions, restoring enzyme activity, and immunization using fusion protein
05/15/2003US20030092623 Inducing proliferation of endothelial cells; use of Bv8 antagonists to treat testicular cancer and hormone dependent tumors; Bv8 is a small protein originally isolated from the skin secretions of the frog Bombina variegata
05/15/2003US20030092622 Preparation stabilized over long time
05/15/2003US20030092620 Use of adipsin/complement factor D in the treatment of metabolic related disorders
05/15/2003US20030092618 Polypeptides, their production and use
05/15/2003US20030092617 Production of vascular endothelial cell growth factor and DNA enconding same
05/15/2003US20030092616 STAT6 activation gene
05/15/2003US20030092615 Nucleic acids, proteins, and antibodies
1 ... 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 ... 3163